What is Pds Biotechnology Corporation's earnings per share (EPS)?

Pds Biotechnology Corporation (PDSB) reported diluted earnings per share of $-0.74 for fiscal year 2025. This represents a 28.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pds Biotechnology Corporation Financials

PDSB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Pds Biotechnology Corporation (PDSB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PDSB FY2025 2026-04-28

External funding, not product revenue, still runs the business as cash burn tracks operating losses almost one-for-one.

In FY2025, operating cash flow and free cash flow were both -$27.8M because capital spending was $0. With EBITDA still -$31.5M and depreciation only $61K, reported losses are translating almost directly into cash use, so the financing need is operational rather than a byproduct of heavy assets or accounting noise.

Leverage ratios look worse even though the liability stack is not expanding, with debt-to-equity at 2.3x and total liabilities at $21.2M. The key shift is that equity shrank to $9.3M, so the higher leverage reading is being driven more by an eroding equity base than by new liabilities, which means near-term liquidity can coexist with a thinner solvency cushion.

The lower burn partly reflects a smaller R&D program, not self-funding scale: research and development fell to $19.0M in FY2025 from $29.4M in FY2022. At the same time, shares outstanding jumped to 54.9M from 38.0M in the latest year, showing that part of the operating runway has been purchased through dilution rather than internally generated cash.

Financial Health Signals

Financial Profile 19/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Pds Biotechnology Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Pds Biotechnology Corporation has a moderate D/E ratio of 2.30. This balance of debt and equity financing earns a leverage score of 55/100.

Liquidity

Pds Biotechnology Corporation's current ratio of 2.98 indicates adequate short-term liquidity, earning a score of 57/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Pds Biotechnology Corporation generates a -372.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -197.9% the prior year.

Piotroski F-Score Weak

2/9

Pds Biotechnology Corporation passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.80x

For every $1 of reported earnings, Pds Biotechnology Corporation generates $0.80 in operating cash flow (-$27.8M OCF vs -$34.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-5.9x

Pds Biotechnology Corporation earns $-5.9 in operating income for every $1 of interest expense (-$31.5M vs $5.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$31.5M

YoY+13.2%

Pds Biotechnology Corporation's EBITDA was -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.2% from the prior year.

Net Income

-$34.5M

YoY+8.3%

Pds Biotechnology Corporation reported -$34.5M in net income in fiscal year 2025. This represents an increase of 8.3% from the prior year.

EPS (Diluted)

$-0.74

YoY+28.2%

Pds Biotechnology Corporation earned $-0.74 per diluted share (EPS) in fiscal year 2025. This represents an increase of 28.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$27.8M

YoY+20.8%

Pds Biotechnology Corporation generated -$27.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 20.8% from the prior year.

Cash & Debt

$26.7M

YoY-35.9%

5Y CAGR-1.5%

10Y CAGR-14.6%

Pds Biotechnology Corporation held $26.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

55M

YoY+44.5%

5Y CAGR+19.8%

Pds Biotechnology Corporation had 55M shares outstanding in fiscal year 2025. This represents an increase of 44.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-372.8%

YoY-174.9pp

5Y CAGR-318.1pp

10Y CAGR-349.9pp

Pds Biotechnology Corporation's ROE was -372.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 174.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$19.0M

YoY-15.7%

5Y CAGR+19.1%

10Y CAGR+0.6%

Pds Biotechnology Corporation invested $19.0M in research and development in fiscal year 2025. This represents a decrease of 15.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Pds Biotechnology Corporation invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

PDSB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$19.0M-15.7%	$22.6M-18.7%	$27.8M-5.7%	$29.4M+161.5%	$11.3M+42.0%	$7.9M
SG&A Expenses	$12.5M-9.0%	$13.8M-10.0%	$15.3M+24.8%	$12.2M+20.2%	$10.2M+46.0%	$7.0M
Operating Income	-$31.5M+13.2%	-$36.3M+15.6%	-$43.0M-3.3%	-$41.7M-94.4%	-$21.4M-43.9%	-$14.9M
Interest Expense	$5.3M+14.6%	$4.7M+10.8%	$4.2M+219.5%	$1.3M	$0	$0
Income Tax	-$1.2M-34.6%	-$869K+38.2%	-$1.4M-17.3%	-$1.2M+73.5%	-$4.5M	$0
Net Income	-$34.5M+8.3%	-$37.6M+12.4%	-$42.9M-5.1%	-$40.9M-141.5%	-$16.9M-13.9%	-$14.8M
EPS (Diluted)	$-0.74+28.2%	$-1.03+25.9%	$-1.39+2.8%	$-1.43-116.7%	$-0.66+25.8%	$-0.89

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$4.6M+8.6%	$4.2M-27.7%	$5.8M	N/A	$6.8M+50.3%	$4.5M-32.5%	$6.7M
SG&A Expenses	N/A	$3.6M+4.5%	$3.4M+4.1%	$3.3M	N/A	$3.4M-18.8%	$4.2M+22.5%	$3.4M
Operating Income	N/A	-$8.1M-6.8%	-$7.6M+16.3%	-$9.1M	N/A	-$10.2M-17.2%	-$8.7M+14.0%	-$10.1M
Interest Expense	N/A	$1.2M-46.4%	$2.1M+130.4%	$931K	N/A	$1.2M+2.3%	$1.2M+0.8%	$1.2M
Income Tax	N/A	$0	$0+100.0%	-$1.2M	N/A	$0+100.0%	-$869K	$0
Net Income	-$7.6M+16.1%	-$9.0M+4.5%	-$9.4M-11.1%	-$8.5M-6.7%	-$8.0M+25.9%	-$10.7M-28.8%	-$8.3M+21.5%	-$10.6M
EPS (Diluted)	N/A	$-0.19+9.5%	$-0.210.0%	$-0.21	N/A	$-0.29-26.1%	$-0.23+23.3%	$-0.30

PDSB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$30.5M-32.8%	$45.4M-23.6%	$59.4M-22.9%	$77.0M+14.6%	$67.2M+117.5%	$30.9M
Current Assets	$28.3M-37.3%	$45.1M-23.7%	$59.1M-22.8%	$76.5M+14.4%	$66.8M+120.3%	$30.3M
Cash & Equivalents	$26.7M-35.9%	$41.7M-26.3%	$56.6M-23.4%	$73.8M+13.1%	$65.2M+126.2%	$28.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$21.2M-19.4%	$26.4M-20.8%	$33.3M+0.8%	$33.0M+727.7%	$4.0M+6.0%	$3.8M
Current Liabilities	$9.5M-44.5%	$17.1M+25.4%	$13.6M+38.8%	$9.8M+161.5%	$3.8M+14.8%	$3.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.3M-51.3%	$19.0M-27.3%	$26.1M-40.6%	$44.0M-30.4%	$63.2M+133.0%	$27.1M
Retained Earnings	-$216.6M-18.9%	-$182.1M-26.0%	-$144.5M-42.3%	-$101.6M-67.3%	-$60.7M-38.6%	-$43.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$30.5M-12.1%	$34.7M-14.3%	$40.5M-13.9%	$47.0M+3.7%	$45.4M-13.5%	$52.5M-13.3%	$60.5M-12.3%	$69.0M
Current Assets	$28.3M+1.3%	$27.9M-17.1%	$33.6M-20.8%	$42.5M-5.7%	$45.1M-13.6%	$52.1M-13.3%	$60.2M-12.4%	$68.7M
Cash & Equivalents	$26.7M+2.0%	$26.2M-17.8%	$31.9M-20.3%	$40.0M-4.1%	$41.7M-16.2%	$49.8M-13.8%	$57.7M-13.4%	$66.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$21.2M-15.9%	$25.3M+3.0%	$24.5M-0.6%	$24.7M-6.4%	$26.4M-13.5%	$30.4M+2.9%	$29.6M-7.1%	$31.8M
Current Liabilities	$9.5M-28.9%	$13.3M+15.6%	$11.5M-36.9%	$18.3M+6.9%	$17.1M-6.8%	$18.3M+17.0%	$15.7M+4.1%	$15.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.3M-2.1%	$9.5M-40.8%	$16.0M-28.6%	$22.4M+17.7%	$19.0M-13.6%	$22.0M-28.8%	$30.9M-16.8%	$37.2M
Retained Earnings	-$216.6M-3.6%	-$209.0M-4.5%	-$200.0M-4.9%	-$190.6M-4.7%	-$182.1M-4.6%	-$174.2M-6.6%	-$163.4M-5.4%	-$155.1M

PDSB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$27.8M+20.8%	-$35.0M-4.1%	-$33.6M-30.8%	-$25.7M-105.9%	-$12.5M+5.0%	-$13.1M
Capital Expenditures	$0-100.0%	$29K	$0	N/A	N/A	N/A
Free Cash Flow	-$27.8M+20.8%	-$35.1M-4.2%	-$33.6M	N/A	N/A	N/A
Investing Cash Flow	$0+100.0%	-$29K	$0	N/A	N/A	$0
Financing Cash Flow	$12.8M-36.7%	$20.2M+23.3%	$16.4M-52.2%	$34.3M-29.9%	$48.9M+63.9%	$29.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$3.7M+37.4%	-$5.9M+35.0%	-$9.1M-0.8%	-$9.0M-9.7%	-$8.2M-2.9%	-$8.0M+9.7%	-$8.9M+10.9%	-$9.9M
Capital Expenditures	$0	$0	N/A	N/A	$0-100.0%	$1	N/A	N/A
Free Cash Flow	-$3.7M+37.4%	-$5.9M	N/A	N/A	-$8.2M-2.9%	-$8.0M	N/A	N/A
Investing Cash Flow	$0	$0	N/A	N/A	$0+100.0%	-$1	N/A	N/A
Financing Cash Flow	$4.2M+1647.9%	$241K-75.8%	$996K-86.4%	$7.3M+4137.4%	$173K+903.6%	$17K+224.9%	-$14K-100.1%	$20.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PDSB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-372.8%-174.9pp	-197.9%-33.6pp	-164.3%-71.5pp	-92.8%-66.1pp	-26.8%+28.0pp	-54.7%
Return on Assets	-113.1%-30.2pp	-82.9%-10.6pp	-72.3%-19.3pp	-53.0%-27.9pp	-25.2%+22.9pp	-48.1%
Current Ratio	2.98+0.3	2.64-1.7	4.33-3.5	7.79-10.0	17.80+8.5	9.28
Debt-to-Equity	2.30+0.9	1.39+0.1	1.27+0.5	0.75+0.7	0.06-0.1	0.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-81.8%+13.5pp	-95.3%-36.2pp	-59.1%-21.1pp	-38.0%+3.9pp	-41.8%+6.9pp	-48.8%-21.8pp	-26.9%+1.6pp	-28.5%
Return on Assets	-24.8%+1.2pp	-26.0%-2.6pp	-23.3%-5.3pp	-18.1%-0.5pp	-17.5%+2.9pp	-20.4%-6.7pp	-13.8%+1.6pp	-15.4%
Current Ratio	2.98+0.9	2.09-0.8	2.92+0.6	2.33-0.3	2.64-0.2	2.84-1.0	3.84-0.7	4.56
Debt-to-Equity	2.30-0.4	2.67+1.1	1.54+0.4	1.10-0.3	1.390.0	1.38+0.4	0.96+0.1	0.86
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Cue Biopharma Inc CUE

$58.4M

MAIA Biotechnology Inc. MAIA

$75.2M

Camp4 Therapeutics Corp. CAMP

$230.6M

Polypid Ltd. PYPD

$87.4M

Vtv Therapeutics VTVT

$115.8M

Frequently Asked Questions

Is Pds Biotechnology Corporation profitable?

No, Pds Biotechnology Corporation (PDSB) reported a net income of -$34.5M in fiscal year 2025.

What is Pds Biotechnology Corporation's EBITDA?

Pds Biotechnology Corporation (PDSB) had EBITDA of -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Pds Biotechnology Corporation's return on equity (ROE)?

Pds Biotechnology Corporation (PDSB) has a return on equity of -372.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pds Biotechnology Corporation's free cash flow?

Pds Biotechnology Corporation (PDSB) generated -$27.8M in free cash flow during fiscal year 2025. This represents a 20.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pds Biotechnology Corporation's operating cash flow?

Pds Biotechnology Corporation (PDSB) generated -$27.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pds Biotechnology Corporation's total assets?

Pds Biotechnology Corporation (PDSB) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Pds Biotechnology Corporation's capital expenditures?

Pds Biotechnology Corporation (PDSB) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Pds Biotechnology Corporation spend on research and development?

Pds Biotechnology Corporation (PDSB) invested $19.0M in research and development during fiscal year 2025.

How many shares does Pds Biotechnology Corporation have outstanding?

Pds Biotechnology Corporation (PDSB) had 55M shares outstanding as of fiscal year 2025.

What is Pds Biotechnology Corporation's current ratio?

Pds Biotechnology Corporation (PDSB) had a current ratio of 2.98 as of fiscal year 2025, which is generally considered healthy.

What is Pds Biotechnology Corporation's debt-to-equity ratio?

Pds Biotechnology Corporation (PDSB) had a debt-to-equity ratio of 2.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pds Biotechnology Corporation's return on assets (ROA)?

Pds Biotechnology Corporation (PDSB) had a return on assets of -113.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pds Biotechnology Corporation's cash runway?

Based on fiscal year 2025 data, Pds Biotechnology Corporation (PDSB) had $26.7M in cash against an annual operating cash burn of $27.8M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Pds Biotechnology Corporation's Piotroski F-Score?

Pds Biotechnology Corporation (PDSB) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pds Biotechnology Corporation's earnings high quality?

Pds Biotechnology Corporation (PDSB) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pds Biotechnology Corporation cover its interest payments?

Pds Biotechnology Corporation (PDSB) has an interest coverage ratio of -5.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Pds Biotechnology Corporation?

Pds Biotechnology Corporation (PDSB) scores 19 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.